Literature DB >> 15616236

Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes.

Daniel J Cox1, Boris P Kovatchev, Linda A Gonder-Frederick, Kent H Summers, Anthony McCall, Kevin J Grimm, William L Clarke.   

Abstract

OBJECTIVE: Hyperglycemia is a common event among patients with type 1 and type 2 diabetes. While the cognitive-motor slowing associated with hypoglycemia is well documented, the acute effects of hyperglycemia have not been studied extensively, despite patients' reports of negative effects. This study prospectively and objectively assessed the effects of hyperglycemia on cognitive-motor functioning in subjects' natural environment. RESEARCH DESIGN AND METHODS: Study 1 investigated 105 adults with type 1 diabetes (mean age 37 years and mean duration of diabetes 20 years), study 2 investigated 36 adults with type 2 diabetes (mean age 50 years and mean duration of diabetes 10 years), and study 3 investigated 91 adults with type 1 diabetes (mean age 39 years and mean duration of diabetes 20 years). Subjects used a hand-held computer for 70 trials over 4 weeks, which required them to complete various cognitive-motor tasks and then measure and enter their current blood glucose reading.
RESULTS: Hyperglycemia (blood glucose >15 mmol/l) was associated with slowing of all cognitive performance tests (P < 0.02) and an increased number of mental subtraction errors for both type 1 and type 2 diabetic subjects. The effects of hyperglycemia were highly individualized, impacting approximately 50% of the subjects.
CONCLUSIONS: Acute hyperglycemia is not a benign event for many individuals with diabetes, but it is associated with mild cognitive dysfunction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15616236     DOI: 10.2337/diacare.28.1.71

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  71 in total

1.  Driving safety: concerns and experiences of parents of adolescent drivers with type 1 diabetes.

Authors:  Daniel J Cox; Linda A Gonder-Frederick; Jaclyn A Shepard; Laura K Campbell; Karen A Vajda
Journal:  Pediatr Diabetes       Date:  2012-05-30       Impact factor: 4.866

2.  Management of Type 1 Diabetes in Older Adults.

Authors:  Ruban Dhaliwal; Ruth S Weinstock
Journal:  Diabetes Spectr       Date:  2014-02

3.  Managing type 1 diabetes in school: Recommendations for policy and practice.

Authors:  Sarah E Lawrence; Elizabeth A Cummings; Danièle Pacaud; Andrew Lynk; Daniel L Metzger
Journal:  Paediatr Child Health       Date:  2015 Jan-Feb       Impact factor: 2.253

Review 4.  Is glycemic variability important to assessing antidiabetes therapies?

Authors:  Boris P Kovatchev
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

5.  What to inject when oral agents fail?

Authors:  Anthony L McCall
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

6.  TFP5, a peptide derived from p35, a Cdk5 neuronal activator, rescues cortical neurons from glucose toxicity.

Authors:  B K Binukumar; Ya-Li Zheng; Varsha Shukla; Niranjana D Amin; Philip Grant; Harish C Pant
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

7.  Persistently high glucose levels in young children with type 1 diabetes.

Authors:  M Tansey; R Beck; K Ruedy; W Tamborlane; P Cheng; C Kollman; L Fox; S Weinzimer; N Mauras; N H White; E Tsalikian
Journal:  Pediatr Diabetes       Date:  2014-12-11       Impact factor: 4.866

8.  Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer's disease.

Authors:  Bhumsoo Kim; Carey Backus; Sangsu Oh; Eva L Feldman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 9.  Diabetes and driving safety: science, ethics, legality and practice.

Authors:  Daniel J Cox; Harsimran Singh; Daniel Lorber; Kathie Hermayer
Journal:  Am J Med Sci       Date:  2013-04       Impact factor: 2.378

Review 10.  Vascular cognitive impairment.

Authors:  Muhammad U Farooq; Philip B Gorelick
Journal:  Curr Atheroscler Rep       Date:  2013-06       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.